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Human T cell lymphotropic virus type 1 (HTLV-1) is the ﬁrst retrovirus described as
a causative agent of human disease. Following adult T cell leukemia/lymphoma and
HLTV-1-associated myelopathy/tropical spastic paraparesis, HTLV-1 uveitis (HU) has been
established as a distinct clinical entity caused by HTLV-1 based on seroepidemiological, clin-
ical, and virological studies. HU is one of the most common causes of uveitis in endemic
areas of Japan and can be a problematic clinical entity all over the world. HU occurs with
a sudden onset of ﬂoaters and foggy vision, and is classiﬁed as an intermediate uveitis.
Analysis of inﬁltrating cells in eyes with HU revealed that the majority of inﬁltrating cells
were CD3+ T cells, but not malignant cells or leukemic cells based on their T cell receptor
usage. HTLV-1 proviral DNA, HTLV-1 protein, and viral particles were detected from inﬁltrat-
ing cells in eyes with HU. HTLV-1-infected CD4+ T cell clones established from inﬁltrating
cells in eyes with HU produced large amounts of various inﬂammatory cytokines, such as
IL-1, IL-6, IL-8, TNF-α, and interferon-γ. Taken together, HU is considered to be caused by
inﬂammatory cytokines produced by HTLV-1-infected CD4+ T cells that signiﬁcantly accu-
mulate in eyes; therefore, topical and/or oral corticosteroid treatment is effective to treat
intraocular inﬂammation in patients with HU. Further investigation is needed to establish a
speciﬁc treatment for HU.
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INTRODUCTION
Retrovirus was ﬁrst described in the 1970s (Temin and Balti-
more, 1972), but its causal relationship with human diseases was
not identiﬁed until the early 1980s when human T cell lym-
photropic virus type 1 (HTLV-1) was identiﬁed as an etiologic
agent of adult T cell leukemia/lymphoma (ATL; Poiesz et al., 1980;
Hinuma et al., 1981; Yoshida et al., 1984). After the discovery of
the link between HTLV-1 and ATL, HLTV-1 was also found to be
a causal agent of HTLV-1-associated myelopathy/tropical spastic
paraparesis (HAM/TSP; Gessain et al., 1985; Osame et al., 1986)
and HTLV-1 uveitis (HU; Mochizuki et al., 1992a,b,c).
HTLV-1 uveitis, the third clinical entity of HTLV-1 infection,
was established by a series of studies in the highly endemic area of
southern Kyushu, Japan. Clinical case reports from this area sug-
gested possible associations of HTLV-1 carrierswith various ocular
manifestations (Ohba et al., 1989). In the 1990s, the ﬁrst set of evi-
dence that indicated the causative implication of HTLV-1 in uveitis
was reported by Mochizuki and colleagues. They showed clinical
and laboratory data consisting of seroepidemiology, clinical fea-
tures, detection of proviral DNA and mRNA of HTLV-1 from
ocular tissues, and detection of viral particles from T cell clones
(TCC) derived from the aqueous humor of the patient (Mochizuki
et al., 1992a,b). Since then, it has been well established that uveitis
is signiﬁcantly related to HTLV-1. Here, we review historical ﬁnd-
ings that contributed to the establishment of the HU entity and
recent advancements that deepen our understanding of HU.
SEROEPIDEMIOLOGY
HTLV-1 infection is known to have unique geographic distri-
bution and is prevalent in Japan, Melanesia, the Caribbean
Islands, Central America, South America, and Central Africa.
It is estimated that 20 million people carry the virus world-
wide (Watanabe, 2011). This virus is etiologically linked with
HU, which is one of the most common causes of uveitis in the
endemic area of Japan and can be a problematic clinical entity
all over the world (Yoshimura et al., 1993; Takahashi et al., 2000;
Merle et al., 2002; Pinheiro et al., 2006; Miyanaga et al., 2009).
Uveitis is a sight-threatening inﬂammatory disorder affecting
the intraocular tissues (Forrester, 1991) and is the third lead-
ing cause of blindness in developed countries. The etiology
of uveitis is categorized as infectious or non-infectious and
varies depending on the genetic background of the population
and the prevalence of the pathogenic agent in the area. Clini-
cally, the etiology of approximately 30% of cases could not be
deﬁned even when careful examinations were performed. A sur-
vey comparing the etiologies of uveitis in different areas of Japan
demonstrated that the proportion of undeﬁned etiologies was
particularly high in southern Kyushu as compared to those in
northern Kyushu and Tokyo. Seroepidemiological comparison
studies (Mochizuki et al., 1992a,b; Shirao et al., 1993) in these
highly endemic and non-endemic areas revealed that the HTLV-1
seroprevalence in patients with idiopathic uveitis was signiﬁcantly
higher than that in the following two control groups: patients
with etiology-deﬁned uveitis and patients with non-uveitic ocu-
lar diseases (Figure 1). This was the ﬁrst clue suggesting that
HTLV-1 infection is signiﬁcantly related to uveitis. Uveitis is
now recognized as a distinct clinical entity related to HTLV-1
and is designated as HU. The seroprevalence of HTLV-1 in the
general Japanese population is known to have decreased after
serological screening tests of HTLV-1 in blood donors started
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FIGURE 1 |The age distribution of the seroprevalence of humanT cell
lymphotropic virus type 1 in a highly endemic area (Miyakonojo,
southern Kyushu, Japan; Shirao et al., 1993 with permission). ,
patients with idiopathic uveitis; , patients with uveitis from a deﬁned
cause; ©, patients with non-uveitic ocular diseases.
in 1987, as blood transfusion and breastfeeding from mother to
child are major routes of viral transmission (Iwanaga et al., 2009).
A recent survey (Miyanaga et al., 2009) in the HTLV-1 endemic
region revealed that the most common clinical entity was still HU,
followed by Vogt–Koyanagi–Harada disease, sarcoidosis, and oth-
ers. However, new cases of HU clearly decreased with time, while
the prevalence of Vogt–Koyanagi–Harada disease and sarcoidosis
has not changedmuch in the last two decades. The age distribution
of HTLV-1 seroprevalence of all patients with uveitis including
HU and of patients with uveitis excluding HU showed that the
HTLV-1 seroprevalence increased with age in patients of both
groups (Yoshimura et al., 1993; Takahashi et al., 2000; Miyanaga
et al., 2009). As for the sex, higher prevalence rates were found
in women, especially after 40 years of age. HTLV-1 is known to
be transmitted by infected lymphocytes in sperm and this may
contribute to the higher prevalence of the disease in women than
in men (Yoshimura et al., 1993; Takahashi et al., 2000; Miyanaga
et al., 2009). As for the prevalence of HU in different parts of the
world, the prevalences of HU in Martinique (Merle et al., 2002)
and Brazil (Rathsam-Pinheiro et al., 2009) are lower than that in
Japan (Yamamoto et al., 1999; Pinheiro et al., 2006). In general,
as migration to metropolitan areas is on the rise, the number of
HTLV-1 carriers in metropolitan areas (for example, Tokyo) is sig-
niﬁcantly increasing (Uchimaru et al., 2008), although the number
of carriers is still the highest in the endemic areas. In consideration
of this evidence, it is estimated that the number of patients with
HU is prospectively increasing in metropolitan areas. Therefore,
careful examination concerning HU is needed for the diagnosis
of uveitis.
CLINICAL MANIFESTATIONS
A recent report indicated that ocular disturbances may be the ﬁrst
manifestations of HTLV-1 infection to come to clinical attention,
in addition to neurologic and rheumatologic signs and symptoms
(Poetker et al., 2011). Therefore, all patients presenting for an
initial diagnosis should be strictly screened for ocular symptoms.
The major symptoms of HU at initial presentation are sudden
onset of ﬂoaters, foggy vision, and blurred vision. Other symp-
toms are pain/burning, itching, and foreign body sensation. These
symptoms appear in all geographic regions according to studies
in Japan, Brazil, and Martinique (Yoshimura et al., 1993; Merle
et al., 2002; Pinheiro et al., 2006). Regarding the anatomic diag-
nosis of uveitis according to the criteria of the International
Uveitis Study Group, most patients had an intermediate degree
of uveitis with moderate or heavy vitreous opacities (ﬁne cells and
lacework-like membranous opacities). The vitreous opacities were
the most impressive ﬁndings and were accompanied by mild iritis
and mild retinal vasculitis, but no uveoretinal lesions (Yoshimura
et al., 1993). The ocular inﬂammation of HU was unilateral or
bilateral (Yoshimura et al., 1993; Merle et al., 2002; Pinheiro et al.,
2006). An association between HU and Graves’ disease has been
reported; HU occurs after the onset of Graves’ disease in all cases
(Yamaguchi et al., 1994). The most recent study (Miyanaga et al.,
2009) reported a similar incidence of HU after Graves’s disease
as that reported by Yamaguchi et al. (1994). Only a few cases
of HU develop into HAM/TSP, but no literature has reported
that ATL develops in patients with HU during their clinical
course. Further patient-tracking research is ongoing to deter-
mine whether HU is a risk factor for the development of ATL or
HAM/TSP.
DIAGNOSIS
Considering seroepidemiological and clinical studies, the diag-
nosis of HU should be based on seropositivity for HTLV-1 with
no systemic evidence of HTLV-1-related diseases (such as ATL or
HAM/TSP) and exclusion of other uveitis entities with deﬁned
causes. Therefore, all clinical entities of uveitis with deﬁned causes
should be excluded by careful ophthalmic and systemic exam-
inations. Patients with HU should not have ophthalmic and
systemic symptoms that are compatible with other types of uveitis
such as Behçet’s disease, Vogt–Koyanagi–Harada syndrome, and
sarcoidosis.
PATHOGENESIS
Eye research has progressed signiﬁcantly in accordance with the
development of modern molecular biological technology, such
as the polymerase chain reaction and ﬂow cytometry. Many
fundamental ﬁndings have been obtained in the study of HU
pathogenesis. The cells ﬂoating in the anterior chamber of
the eye with HU consisted of lymphocytes with a small pro-
portion of macrophages. No malignant cells or leukemic cells
were detected in the aqueous humor of the patients with HU
(Masuoka et al., 1995). The majority of inﬁltrating cells in the
aqueous humor of patients with HU were CD3+ T cells (Ono
et al., 1997). Analysis by polymerase chain reaction of ocular-
inﬁltrating cells revealed that HTLV-1 proviral DNA was detected
in almost all patients with HU. However, proviral DNA was not
detected in patients with uveitis of other deﬁned etiology who
were seropositive for HTLV-1. These data suggest that HTLV-
1-infected cells are present at the local site of HU (Ono et al.,
1997). Furthermore, expression of viral mRNA was detected by
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reverse transcriptase-polymerase chain reaction from the inﬂam-
matory cells in the aqueous humor. More direct evidence of
HTLV-1 in the pathogenesis of HU has been provided by using
TCC derived from intraocular tissues of eyes with HU. Provi-
ral DNA of HTLV-1 was identiﬁed in TCC from the ocular ﬂuid
(Sagawa et al., 1995). Immunohistochemical staining showed that
HTLV-1 env and gag proteins were detectable in HTLV-1 provirus-
positive TCC. Furthermore, electron microscopic observation of
the TCC identiﬁed HTLV-1 virus particles, the mean diameter of
which was 102 nm (Sagawa et al., 1995). Most HTLV-1-infected
TCC had a CD3+CD4+CD8− phenotype and had polyclonal
TCRα usage (Sagawa et al., 1995). The HTLV-1-infected TCC
produced signiﬁcant amounts of IL-1α, IL-2, IL-3, IL-6, IL-8,
IL-10, TNF-α, IFN-γ, and GM-CSF, which are potent cytokines
capable of inducing immune reactions and inﬂammation at the
intraocular tissue level (Sagawa et al., 1995). These data sug-
gest that cytokine production by HTLV-1-infected T cells in
intraocular tissues is responsible for intraocular inﬂammation,
i.e., uveitis (Figure 2). In addition to this molecular biologi-
cal/immunological evidence, virological research supported the
pathogenicity of HTLV-1 in the eye by the following three pieces
of evidence: (1) the HTLV-1 provirus load in patients with HU
is signiﬁcantly higher than that in asymptomatic carriers with-
out uveitis (Ono et al., 1995); (2) the proviral load in peripheral
blood mononuclear cells correlates with the intensity of intraoc-
ular inﬂammation (Ono et al., 1998); and (3) the proviral load
in the eyes of patients with HU is signiﬁcantly higher than that
present in peripheral blood mononuclear cells (Ono et al., 1997).
Serologic data showed that the antibody level against HTLV-1 in
patients with HU was similar to that in asymptomatic carriers
of HTLV-1, but was lower than that in patients with HTLV-
1-associated myelopathy (Mochizuki et al., 1992b). Antibody to
the virus in the aqueous humor was also detected in all tested
samples from patients with HU. Flow cytometry analysis indi-
cated that the CD4 fraction was elevated and the CD8 fraction
was decreased in peripheral lymphocytes from patients with HU,
thereby elevating the CD4/8 ratio in the HU group as compared
with the seronegative group. Furthermore, the CD25 fraction of T
lymphocytes with expression of interleukin 2 receptors was signif-
icantly elevated in patients with HU. The serum levels of soluble
interleukin 2 receptors (sIL2R or sCD25) were also signiﬁcantly
higher in patients with HU than in seronegative healthy con-
trols (Yoshimura et al., 1993). Taken together, these laboratory
data suggest that the immune-mediated mechanism, particularly
involving CD4+ T cells, plays a critical role in the pathogenesis
of HU.
THERAPY
Immunopathogenesis studies of HU showed that the major-
ity of ocular-inﬁltrating cells are inﬂammatory cells, but not
malignant cells. Also, a series of studies showed that HU is
caused by inﬂammatory cytokines produced by HTLV-1-infected
CD4+ T cells that signiﬁcantly accumulate in the eyes of the
patients. Furthermore, the addition of corticosteroids in the
culture medium suppressed the cytokine production (Sagawa
et al., 1995). Therefore, corticosteroid treatment is effective for
treating the intraocular inﬂammation of patients with HU by
FIGURE 2 |The majority of infiltrating cells in eyes with HTLV-1 uveitis
are inflammatory cells and not malignant or leukemic cells. HTLV-1
uveitis is caused by inﬂammatory cytokines produced by HTLV-1-infected
CD4+ T cells that signiﬁcantly accumulate in the eyes of patients.
suppressing the cytokine production of HTLV-1-infected CD4+
T cells. Clinical management should be performed according to
the degree of ocular inﬂammation. HU with a mild degree of ocu-
lar inﬂammation can be managed by topical non-corticosteroidal
or corticosteroidal anti-inﬂammatory drugs. A sub-Tenon’s injec-
tion of corticosteroids may be used when the patients have
moderate inﬂammatory activity in the vitreous cavity. If the vit-
reous inﬂammatory activity and the retinal vasculitis are severe,
oral corticosteroids should be given, but the long-term adminis-
tration of a systemic corticosteroid should be avoided. In most
cases, intraocular inﬂammation is markedly improved with these
therapies and complete remission is achieved. The visual prog-
nosis for cases of HU is generally good with these corticosteroid
treatments, although approximately 60% of patients experience
recurrences of uveitis (Yoshimura et al., 1993).
CONCLUSION
We reviewed the seroepidemiological, clinical, molecular biolog-
ical, and virological studies that established the HU entity and
clariﬁed the immunopathogenesis and the clinical management
of HU. Corticosteroid is the only effective treatment for HU to
suppress the cytokines produced by inﬁltrating HTLV-1-infected
cells; however, it is unknown whether long-term corticosteroid
treatment adversely affects patients with HU. Many mechanisms
in HU remain unclear, such as how HTLV-1-infected CD4+ cells
break down the ocular blood barrier and why the vitreous humor
is the major site of inﬂammation (Figure 2). We may be able to
ﬁnd more effective treatments if we can understand the mech-
anism of HU in more detail. Recent studies have shown new
insights into HTLV-1 infection and pathogenesis by pursuing the
molecular functions of HTLV-1 basic leucine zipper factor and Tax
(Yasunaga and Matsuoka, 2011). However, few studies have been
conducted to apply these new ﬁndings to HU research. Further
investigation is needed to establish a speciﬁc treatment for HU.
HU results from HTLV-1 infection; therefore, the most important
means of preventing this disease is by spreading the knowledge
about HTLV-1.
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